<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-0015</journal-id>
<journal-title><![CDATA[Medicina Legal de Costa Rica]]></journal-title>
<abbrev-journal-title><![CDATA[Med. leg. Costa Rica]]></abbrev-journal-title>
<issn>1409-0015</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Medicina Forense]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-00152017000100059</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia a 5 años de pacientes con cáncer de mama triple negativo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quirós Alpízar]]></surname>
<given-names><![CDATA[José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinoza Morales]]></surname>
<given-names><![CDATA[Karla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Integral Ebenezer  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>59</fpage>
<lpage>72</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-00152017000100059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-00152017000100059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-00152017000100059&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El presente estudio es un análisis de la supervivencia de pacientes con cáncer de mama triple negativos durante un lapso de 5 años, del 2006 al 2012, en el Hospital San Juan de Dios, San José, Costa Rica. El cáncer de mama es una enfermedad heterogénea, es la principal causa de muerte en las mujeres costarricenses. El cáncer de mama se puede clasificar de acuerdo a la expresión de receptores hormonales (estrógeno, progesterona) y HER-2, determinados mediante técnicas inmunohistoquímicas. A los carcinomas que resultan negativos para estas pruebas se les denomina: carcinomas triple negativos. En el presente estudio, el 18% (I.C. 95% 12.79-23.4) de los carcinomas de mama fueron tumores triple negativos, el cual representa las características histológicas más agresivas, de mal pronóstico, pacientes más jóvenes y con una supervivencia más corta que en otros tipos de tumores de mama. La supervivencia global, del presente estudio, para los pacientes con cáncer de mama triple negativos fue de 75.4%(IC95%53.0-88.2). La supervivencia a 5 años de las pacientes con este tipo de tumores fue a los 60 meses de 96.0% (IC 95% 74.8-99.4) en estadio I, de 82.6% (IC 95% 69.3-90.6) para las pacientes con estadio II y un 87.5% (IC 95% 70.1-95.1) para las pacientes con estadio III. Solo dos pacientes contaron con estadio IV las cuales no alcanzaron una sobrevida a los 60 meses.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract This study is a 5 year survival analysis in breast cancer triple negative patients, from 2006 to 2012, at the San Juan de Dios Hospital, San José, Costa Rica. Breast cancer is a heterogeneous pathology and it&#8217;s the main death cause in Costa Rican women. Breast cancer can be classified according to the expression of hormonal receptor (estrogen, progesterone) and HER-2, determined with immunohistochemical techniques. Breast carcinomas that result negative for these results are denominated triple negative carcinomas. Results show that 18% of the studied population (I.C. 95% 12.79-23.4) of breast carcinomas were triple negative, these represent more aggressive histological characteristics, worst prognosis, younger patients and a smaller survival rate compared to other types of breast carcinomas. Five year survival with this type of tumor was 60 months in 96.0% (IC 95% 74.8-99.4), 82.6% (IC 95% 69.3-90.6) for patients at stage II, and 87.5% (IC 95% 70.1-95.1) in patients at stage III. Only two patients had stage IV and didn&#8217;t reach a 60-month survival.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama triple negativos]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[inmunohistoquímica]]></kwd>
<kwd lng="es"><![CDATA[cáncer de mama]]></kwd>
<kwd lng="en"><![CDATA[Triple negative breast cancer]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[immuhistochemistry]]></kwd>
<kwd lng="en"><![CDATA[breast cancer]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Incidencia de tumores malignos más frecuentes en mujeres en Costa Rica 1995-2006]]></source>
<year>2008</year>
<publisher-name><![CDATA[Unidad de Estadística, Registro Nacional de Tumores]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corvalan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene expression profiles for therapeutic decisions in breast cancer]]></article-title>
<source><![CDATA[Revista Médica de Chile]]></source>
<year>2007</year>
<volume>135</volume>
<page-range>257-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[c-erbB-2 in breast cancer: development of a clinically useful marker]]></article-title>
<source><![CDATA[Seminars in oncology]]></source>
<year>2002</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>231-45</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fausto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Patología Estructural y Funcional]]></source>
<year>2005</year>
<edition>8</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slamon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Leyland]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shak]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bajamonde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Norton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2]]></article-title>
<source><![CDATA[The New England journal of medicine]]></source>
<year>2001</year>
<volume>344</volume>
<page-range>783-92</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Osborne]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Allred]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer]]></article-title>
<source><![CDATA[Journal of clinical oncology]]></source>
<year>1999</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1474-81</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reis-Filho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tutt]]></surname>
<given-names><![CDATA[A. N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal-like breast cancer: a critical review]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>2008</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>108-18</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleator]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heller]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Coombes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple negative breast cancer: therapeutic options]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2007</year>
<numero>8</numero>
<issue>8</issue>
<page-range>235-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mieog]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Hage]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Putter]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Bartelink]]></surname>
<given-names><![CDATA[H. Van de Vijver, M]]></given-names>
</name>
<name>
<surname><![CDATA[Van de Velde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of histological grade on prognosis in very young breast cancer patients: pooled analysis of four EORTC trials]]></article-title>
<source><![CDATA[European Journal of Cancer Supplements]]></source>
<year>2008</year>
<volume>6</volume>
<page-range>194</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Houssami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boyages]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast Cancer in Young Women]]></article-title>
<source><![CDATA[Aust Fam Physician]]></source>
<year>2005</year>
<volume>34</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>851-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samphao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rafferty]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Michaelson]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Specht]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>2009</year>
<volume>198</volume>
<page-range>538-43</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of breast cancer in young women]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2010</year>
<volume>126</volume>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirós]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Monge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinomas triple negativos de la glándula mamaria: características clínico-patológicas]]></article-title>
<source><![CDATA[Acta Medica Costarricense]]></source>
<year>2010</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>90-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirós]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama en mujeres jóvenes características clínicas y patológicas]]></article-title>
<source><![CDATA[Revista Médica de la Universidad de Costa Rica]]></source>
<year>2010</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amadou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hainaut]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Romieu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer in Latin America: global burden, patterns, and risk factors]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2014</year>
<volume>56</volume>
<page-range>547-54</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Porterfield]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Varghese]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advancing cervical cancer prevention in India: Implementation science priorities]]></article-title>
<source><![CDATA[The Oncologist]]></source>
<year>2013</year>
<volume>18</volume>
<page-range>1285-97</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Houssami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boyages]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast Cancer in Young Women]]></article-title>
<source><![CDATA[Aust Fam Physician]]></source>
<year>2005</year>
<volume>34</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>851-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmichael]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and breast cancer: a review of the literature]]></article-title>
<source><![CDATA[The Breast]]></source>
<year>2004</year>
<volume>13</volume>
<page-range>85-92</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cress]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Parise]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caggiano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the socalled triple-negative phenotype]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2007</year>
<volume>109</volume>
<page-range>1721-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinación de la efectividad de cinco protocolos de extracción de ADN a partir de material parafinado para estudios moleculares]]></article-title>
<source><![CDATA[Rev med UCR]]></source>
<year>2007</year>
<volume>1</volume>
<page-range>10-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irvin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is triple-negative breast cancer?]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2008</year>
<volume>44</volume>
<page-range>2799-805</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nasrin]]></surname>
<given-names><![CDATA[Amirifard]]></given-names>
</name>
<name>
<surname><![CDATA[Edris]]></surname>
<given-names><![CDATA[Sadeghi]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[Choubsaz]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple-Negative Breast Cancer Survival in Kurdish Patients Nasrin Amirifard1, Edris Sadeghi*. Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch]]></article-title>
<source><![CDATA[J. App. Med. Sci]]></source>
<year>2016</year>
<volume>4</volume>
<numero>7F</numero>
<issue>7F</issue>
<page-range>2732-5</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mary Jo Lund]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Katrina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Trivers]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Peggy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Ralph]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Brian Leyland-Jones]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Otis]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Brawley]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Elaine]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Flagg]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Ruth]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Regan]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[Sheryl G]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gabram]]></surname>
<given-names><![CDATA[Æ]]></given-names>
</name>
<name>
<surname><![CDATA[William Ele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ping-Ping]]></surname>
<given-names><![CDATA[Bao]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[Cai]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[Peng]]></given-names>
</name>
<name>
<surname><![CDATA[Kai]]></surname>
<given-names><![CDATA[Gu]]></given-names>
</name>
<name>
<surname><![CDATA[Yinghao]]></surname>
<given-names><![CDATA[Su]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[Ou Shu]]></given-names>
</name>
<name>
<surname><![CDATA[Ying]]></surname>
<given-names><![CDATA[Zheng]]></given-names>
</name>
</person-group>
<source><![CDATA[Body mass index and weight change in relation to triple-negative breast cancer survival]]></source>
<year>2015</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
